JSLLJeena Sikho Lifecare Ltd.

    Jeena Sikho Lifecare Q2 FY27 Results: Consolidated Net Profit ₹36.63 Crore on Total Income of ₹233 Crore

    • Earnings
    • Ayurvedic healthcare

    Jeena Sikho Lifecare (NSE: JSLL) reported consolidated total income of ₹233.19 crore and net profit of ₹36.63 crore for the quarter ended 30 Sep 2026, it said in a filing on 14 Nov 2026. Standalone total income was ₹232.82 crore and standalone net profit ₹36.34 crore.

    Key highlights

    Consolidated

    Including its subsidiaries

    • Total income: ₹233.19 crore, up 21.9% YoY and down 2.3% QoQ
    • Net profit and EPS: ₹36.63 crore, down 37.7% YoY; basic EPS ₹2.95
    • Other income: ₹-1.94 crore, against ₹1.44 crore a year earlier and ₹14.33 crore in Q1 FY27
    • Finance costs: ₹4.04 crore, down 7.1% YoY

    Standalone

    The company on its own, without its subsidiaries

    • Total income: ₹232.82 crore, up 21.7% YoY and down 2.3% QoQ
    • Net profit and EPS: ₹36.34 crore, down 38.2% YoY; basic EPS ₹2.92
    • Other income: ₹-2.31 crore, against ₹1.44 crore a year earlier
    • Final dividend: ₹4.50 per equity share approved at the AGM held 28 Sep 2026

    Summary

    Consolidated ₹ crore
    ParticularsQ2 FY27Q2 FY26YoYQ1 FY27QoQ
    233.19191.29+21.9%238.73-2.3%
    36.6358.75-37.7%65.89-44.4%
    EPS, basic (₹)2.954.73-37.6%5.30-44.3%

    Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

    Net profit fell faster than income. Total income rose 21.9% against a year earlier, while net profit fell 37.7%. Other income turned negative at ₹-1.94 crore, which is -0.8% of total income, compared with ₹1.44 crore in Q2 FY26. Revenue from operations rose 23.9% to ₹235.13 crore, so the gap is in the other lines of the statement rather than in the top line.

    Depreciation rose 58.6% to ₹16.49 crore, from ₹10.40 crore a year earlier, and tax expense fell 35.4% to ₹12.90 crore. Tax was 26.0% of profit before tax of ₹49.53 crore, close to the 25.4% of the year-earlier quarter. Finance costs of ₹4.04 crore are 1.7% of total income, so borrowing cost is a small part of the quarter's expenses.

    Against the previous quarter, net profit fell 44.4% while total income fell 2.3%. The filing does not give a reason for the change in other income.

    Standalone ₹ crore
    ParticularsQ2 FY27Q2 FY26YoYQ1 FY27QoQ
    232.82191.29+21.7%238.42-2.3%
    36.3458.79-38.2%65.69-44.7%
    EPS, basic (₹)2.924.73-38.3%5.28-44.7%

    Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

    The standalone figures follow the consolidated pattern. Total income rose 21.7% YoY to ₹232.82 crore, and net profit fell 38.2% to ₹36.34 crore. Standalone other income was ₹-2.31 crore, or -1.0% of total income, and profit before tax was ₹49.24 crore.

    Standalone depreciation rose 58.0% to ₹16.43 crore, and tax expense of ₹12.90 crore was 26.2% of profit before tax. Standalone basic EPS was ₹2.92 against ₹4.73 a year earlier.

    Consolidated net profit of ₹36.63 crore is ₹0.29 crore higher than the standalone ₹36.34 crore. Consolidated net profit fell 37.7% YoY, slightly less than the standalone fall of 38.2%.

    The filing says the Derabassi hospital land and building were sold, and the hospital was taken back on lease to ensure continued operations. The sale proceeds are not stated. The filing also reports a final dividend of ₹4.50 per share approved at the AGM held on 28 Sep 2026, with the record and payment dates not stated.

    The consolidated statement covers two subsidiaries, Jeena Sikho International LLC and Jeena Green Resources Private Limited. The auditor did not review the interim results of two subsidiaries whose total assets were ₹213.34 crore, and relied on other auditors' reports for them.

    Inference

    The filing reports that 23,374 equity shares were allotted under ESOS 2024, raising paid-up capital slightly, and that 4.5 lakh shares from warrant conversion await stock exchange approval after a balance payment of ₹7.90 crore.

    Ayugenomics Private Limited was incorporated on 11 Nov 2026, with the company subscribing to 60% of its equity for ₹3.00 lakh. The filing does not state the business plans or funding of the subsidiary beyond that initial subscription, nor the reason for the hospital sale and leaseback.

    Filed with BSE on . Reference: Original filing (PDF)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Related posts

    All Jeena Sikho Lifecare Ltd. articles